EA200971020A1 - Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla - Google Patents
Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором splaInfo
- Publication number
- EA200971020A1 EA200971020A1 EA200971020A EA200971020A EA200971020A1 EA 200971020 A1 EA200971020 A1 EA 200971020A1 EA 200971020 A EA200971020 A EA 200971020A EA 200971020 A EA200971020 A EA 200971020A EA 200971020 A1 EA200971020 A1 EA 200971020A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- spla
- inhibitors
- cvd
- treatment
- dyslipidemia
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 9
- 208000032928 Dyslipidaemia Diseases 0.000 title abstract 3
- 208000017170 Lipid metabolism disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 102000015439 Phospholipases Human genes 0.000 title 1
- 108010064785 Phospholipases Proteins 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 6
- 208000037998 chronic venous disease Diseases 0.000 abstract 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91591007P | 2007-05-03 | 2007-05-03 | |
| US96959107P | 2007-08-31 | 2007-08-31 | |
| US87486907A | 2007-10-18 | 2007-10-18 | |
| PCT/US2008/062577 WO2008137803A1 (en) | 2007-05-03 | 2008-05-02 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200971020A1 true EA200971020A1 (ru) | 2010-10-29 |
Family
ID=39943969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200971020A EA200971020A1 (ru) | 2007-05-03 | 2008-05-02 | Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2154958A4 (enExample) |
| JP (1) | JP2010526152A (enExample) |
| CN (1) | CN101742907A (enExample) |
| AU (1) | AU2008247451A1 (enExample) |
| BR (1) | BRPI0811486A2 (enExample) |
| CA (1) | CA2686157A1 (enExample) |
| EA (1) | EA200971020A1 (enExample) |
| WO (1) | WO2008137803A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012514652A (ja) * | 2009-01-08 | 2012-06-28 | アンセラ・ファーマシューティカルズ・インコーポレイテッド | 心血管疾患および脂質異常症を治療するための分泌ホスホリパーゼａ２（ｓｐｌａ２）インヒビターとナイアシン薬との組成物および方法 |
| RU2483707C1 (ru) * | 2012-05-04 | 2013-06-10 | Лира Талгатовна Гильмутдинова | Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн |
| CN115040508A (zh) * | 2022-07-28 | 2022-09-13 | 上海市同仁医院 | 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| KR20010071197A (ko) * | 1998-05-01 | 2001-07-28 | 피터 지. 스트링거 | ｓＰＬＡ2 억제제 에스테르 |
| AU2001236440A1 (en) * | 2000-01-25 | 2001-08-07 | Eli Lilly And Company | Method for the treatment of inflammation with spla2 inhibitors |
| WO2002008189A1 (en) * | 2000-07-24 | 2002-01-31 | The University Of Queensland | Compounds and inhibitors of phospholipases |
| TWI314457B (enExample) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
| US20060094693A1 (en) * | 2004-09-21 | 2006-05-04 | Point Therapeutics, Inc. | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions |
| US7666898B2 (en) * | 2005-11-03 | 2010-02-23 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
-
2008
- 2008-05-02 CN CN200880023061A patent/CN101742907A/zh active Pending
- 2008-05-02 EA EA200971020A patent/EA200971020A1/ru unknown
- 2008-05-02 JP JP2010507578A patent/JP2010526152A/ja active Pending
- 2008-05-02 BR BRPI0811486-2A2A patent/BRPI0811486A2/pt not_active IP Right Cessation
- 2008-05-02 EP EP08747605A patent/EP2154958A4/en not_active Withdrawn
- 2008-05-02 AU AU2008247451A patent/AU2008247451A1/en not_active Abandoned
- 2008-05-02 CA CA002686157A patent/CA2686157A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062577 patent/WO2008137803A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2686157A1 (en) | 2008-11-13 |
| EP2154958A1 (en) | 2010-02-24 |
| EP2154958A4 (en) | 2011-05-04 |
| AU2008247451A1 (en) | 2008-11-13 |
| CN101742907A (zh) | 2010-06-16 |
| JP2010526152A (ja) | 2010-07-29 |
| WO2008137803A1 (en) | 2008-11-13 |
| BRPI0811486A2 (pt) | 2014-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200700924A1 (ru) | Соединения ряда дибензиламина и их производные | |
| ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
| NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| EA200800356A1 (ru) | Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| BR0315381A (pt) | Composto ou um sal farmaceuticamente aceitável deste, composição farmacêutica, e, métodos para inibir a atividade da enzima dipeptidil peptidase-iv em um mamìfero em necessidade disto, para tratar diabetes em um mamìfero em necessidade disto, para tratar diabete não dependente de insulina (tipo 2) em um mamìfero em necessidade disto, para tratar hiperglicemia em um mamìfero em necessidade disto, para tratar a obesidade em um mamìfero em necessidade disto, para tratar um ou mais distúrbios de lipìdios selecionados do grupo de dislipidemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, hdl baixo e ldl alto em um mamìfero em necessidade disto, e para tratar em um mamìfero em necessidade disto uma ou mais condições | |
| CL2012001124A1 (es) | Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl. | |
| CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
| EA200602273A1 (ru) | Замещённые гетероарильные и фенилсульфамоильные соединения | |
| MX2009003727A (es) | Acidos y esteres boronicos como inhibidores de amida hidrolasa de acido graso. | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| MX2007001553A (es) | Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados. | |
| BR112014004444A2 (pt) | composições e métodos que compreendem uma variante de enzima lipolítica | |
| MX2009008099A (es) | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. | |
| EP2032715A4 (en) | METHOD AND MATERIALS FOR THE MANUFACTURE OF SIMVASTATIN AND RELATED COMPOUNDS | |
| EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| EP4403213A3 (en) | Methods for reducing cardiovascular risk | |
| AP2002002427A0 (en) | Ppar compounds. | |
| MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
| WO2010079431A3 (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie |